Bisphosphonate Therapy with Zoledronate or Tenofovir Switching to Improve Low Bone Mineral Density in HIV-Infected Adults: a Strategic, Randomised Trial

大多数艾滋病毒阳性的澳大利亚人服用替诺福韦，这是所有艾滋病毒治疗指南中的“首选”药物，可能会持续几十年，因为艾滋病毒治疗是终身的，而且很少有新的艾滋病毒药物。40%的艾滋病毒阳性成年人骨密度低，艾滋病毒阳性成年人更容易骨折。在所有抗艾滋病药物中，替诺福韦导致的骨质流失最多。这项试验比较了两种方法：一种改善骨密度的药物和将替诺福韦换成另一种药物。这种“治疗vs转换”的方法是世界上第一个治疗艾滋病毒的方法。

Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.